

Neuropathological Changes in Brain Cortex and Hippocampus in a Rat Model of Alzheimer's Disease

Maliheh Nobakht^{*1,2,3,4}, Seyed Mohammad Hoseini¹, Pejman Mortazavi¹, Iraj Sohrabi¹,
Banafshe Esmailzade^{5,6}, Nahid Rahbar Rooshandel¹, Shila Omidzahir⁷

¹Dept. of Pathology, Faculty of Specialized Veterinary Science, Science and Research Branch Islamic Azad University, Tehran, Iran; ²Dept. of Histology and Neuroscience, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; ³Anti-Microbial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran; ⁴Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; ⁵Dept. of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; ⁶Dept. of Anatomy, School of Medicine, Bushehr University of Medical Science, Bushehr, Iran; ⁷Veterinary Medicine, Faculty of Specialized Veterinary Science, Tehran University of Veterinary Sciences, Tehran, Iran

Received 5 September 2010; revised 8 January 2011; accepted 15 January 2011

ABSTRACT

Background: Alzheimer's disease (AD) is a neurodegenerative disorder with progressive loss of cognitive abilities and memory loss. The aim of this study was to compare neuropathological changes in hippocampus and brain cortex in a rat model of AD. **Methods:** Adult male Albino Wistar rats (weighing 250-300 g) were used for behavioral and histopathological studies. The rats were randomly assigned to three groups: control, sham and β -amyloid (A β) injection. For behavioral analysis, Y-maze and shuttle box were used, respectively at 14 and 16 days post-lesion. For histological studies, Nissl, modified Bielschowsky and modified Congo red staining were performed. The lesion was induced by injection of 4 μ L of A β (1-40) into the hippocampal fissure. **Results:** In the present study, A β (1-40) injection into hippocampus could decrease the behavioral indexes and the number of CA1 neurons in hippocampus. A β injection CA1 caused A β deposition in the hippocampus and less than in cortex. We observed the loss of neurons in the hippocampus and cerebral cortex and certain subcortical regions. Y-maze test and single-trial passive avoidance test showed reduced memory retention in AD group. **Conclusion:** We found a significant decreased acquisition of passive avoidance and alternation behavior responses in AD group compared to control and sham group ($P < 0.0001$). Compacted amyloid cores were present in the cerebral cortex, hippocampus and white matter, whereas, scattered amyloid cores were seen in cortex and hippocampus of AD group. Also, reduced neuronal density was indicated in AD group. *Iran. Biomed. J. 15 (1 & 2): 51-58, 2011*

Keywords: Alzheimer's disease (AD), Hippocampus, β -amyloid (A β), Neuropathological changes

INTRODUCTION

Alzheimer's disease (AD) is a complex, chronic and devastating disease affecting a high percentage of the population over 65 years of age [1]. Oxidative stress may underlie the progressive neurodegeneration characteristic of AD [2]. The neurodegenerative process in AD may involve β -amyloid (A β) toxicity. Neurotoxicity of A β can be demonstrated *in vitro*, and appears to involve oxidative stress [3]. Aging, the major risk factor for AD [4], leads to loss of free radical scavenging ability by endogenous mechanisms [5]. Free radical-mediated damage to neuronal

membrane components also is implicated in aging, as well as the etiology of AD [6]. Most cases occur sporadically, although a small proportion is inherited as an autosomal dominant disorder. Several gene loci are involved in familial cases, including the amyloid precursor protein gene on chromosome 21, the presenilin-1 gene on chromosome 14 and the presenilin-2 gene on chromosome 1. There is an increased incidence of sporadic Alzheimer's disease in individuals with ApoE e4 genotype on chromosome 19. Females are affected almost twice as frequently as males [7].

AD is associated with cholinergic neuronal loss [8] and characterized by deficits in memory and

*Corresponding Author; Tel. (+98-912) 3907045; Fax: (+98-21) 8805 8689 133; E-mail: manob@iums.ac.ir

cognition that are associated with significant losses of presynaptic cholinergic function in the brain, particularly the nucleus basalis [9, 10]. The major microscopic abnormalities of AD, which form the basis of the histologic diagnosis, are neuritic plaques and neuro-fibrillary tangles. There is progressive and eventually severe neuronal loss and reactive gliosis in the same regions that bear the burden of plaques and tangles. Neuritic plaques are focal, spherical collections of dilated, tortuous, neuritic processes often around a central amyloid core, which may be surrounded by clear halo [11].

A β has been shown to provoke neuronal death, decreased synaptic plasticity, aberrant sprouting of growing axons, chronic inflammation and hyperphosphorylation of tau [12]. Deposition of A β is an early and critical event in the pathogenesis of AD [13], first forming in temporal cortical regions including the hippocampus [14], a region implicated in memory formation [15]. It was proposed that A β aggregates to form neurotoxic plaques, which lead to neurodegeneration accompanied by dementia. The present experiment was to evaluate the effects of injection of A β intrahippocampal on memory tasks in adult male rats measured by behavioral tests (Y-maze and passive avoidance) and histopathological examination. Inhibitory avoidance (also called passive avoidance) is acquired in only one trial, where the subject is punished for doing something such as entering a new compartment (test) [16]. Cell death can occur by two morphologically and biochemically distinct pathways: necrosis and apoptosis. These two pathways are not mutually exclusive, and both types of death have been observed in the brain in AD.

Apoptotic cells show morphological changes that include condensation and fragmentation of heterochromatin, membrane blebbing, loss of the nuclear envelope, and cellular fragmentation into apoptotic bodies, whereas most of the organelles remain intact [17]. Similarly, small arterioles, venules, and capillaries within cerebral cortex also frequently bear amyloid deposits [18]. In the present study, we have shown comparative neuropathological changes between hippocampus and brain cortex after A β bilateral injection into each hippocampus in CA1.

MATERIALS AND METHODS

Animals. Thirty adult male Albino Wistar rats

(weighing 250-300 g, 8-10 weeks old), obtained from the Animal Center of Iran Medical College, were used in this experiment. The rats were randomly assigned to three groups with ten animals in each group: A) Control group age-matched rat, B) Sham-lesioned group, injected with deionized water and C) Experimental-lesioned group, injected with A β (1-40). All animal procedures were performed in accordance with the Guide to the Iranian Council for Use and Care of Animals and were approved by the Animal Research Ethical Committee of Tehran University of Medical sciences.

Animal surgery. Synthetic A β -40 amyloid protein (Sigma, CA, USA) was dissolved in deionized water at a concentration of 2 nmol/ μ l and then aliquot and stored at -70°C before use. Rats were anesthetized with intraperitoneal injection of ketamine and xylazine (60 and 20 mg/kg body weight, respectively, Alfasan, Woerden, Holland). Animals were placed in the stereotaxic frames (Stoelting Co. USA), the skull exposed and disinfected with betadine. An incision was made into the scalp and the cranium drilled to a depth of 2.6 mm. The place was localized at 2.0 mm medial-lateral and 3.8 mm posterior-anterior to bregma, following by Paxinos and Watson atlas (1986). In AD group, 4 μ l solution of A β 40 amyloid protein was bilaterally injected into each hippocampus with a 10 μ l Hamilton syringe over a period of 12 min. The infusion was made over 10 minutes, retained 2 minutes, and retarded 2 minutes to allow for complete diffusion of drug [1]. The needle was slowly withdrawn after injection. Sham group underwent the same procedures except that only deionized water was injected.

Y-maze task. Y-maze test was initiated 14 day after A β injection. All testing was carried out from 3 p.m. to 6 p.m. The Y-maze was a Y-shaped plexiglas holding cage with a 40 cm length, 30 cm height and 15 cm width. Rats were allowed to freely discover the maze for 8 min observation period. Air circulation equipment in continuous operation provided masking noise of 40 dB. Alternation was defined as successive entries into the three arms on overlapping triplet sets. The alternation percentage was calculated as the ratio of actual to possible alternations (defined as the total number of arm entries minus two) [19].

Single-trial passive avoidance test. This test was performed 16 days after surgery. The apparatus (Behin Paya Tajhiz Co., Tehran) consisted of light

and dark compartments of equal size connected by a small central guillotine door. Electric shocks were given to the rats in the dark compartment with the grid floor. All rats were adapted to the apparatus on the first and second days of testing for 5 min. On the third day, the rats individually entered the light compartment and remained there for 2 min, then the guillotine door was opened and the rat entered the dark compartment and received a 2 s, 1 mA electric footshock. For retention, 24 hours later, each rat was again placed in the light compartment. The latency to step through the dark compartment (maximum 600 s) was measured and recorded as the index for the passive avoidance behavior. The behavioral observations were carried out between 12:00 and 15:00 [19].

Histological procedure. After the behavioral test, animals were killed 12 weeks after surgery and brains were removed and dissected into hippocampal and cortex blocks. After the behavioral test, all rats were anesthetized with ketamine and xylazine and perfused with 4% paraformaldehyde in 0.1 mol/L phosphate buffer solution (pH 7.4). Then, the brains were removed and fixed in the similar solution for 24 h. Following routine processing in paraffin, serial coronal sections of the brain were cut at 8 μ m thickness in a rotary microtome (Leitz, 1512, Germany). The parts of each rat brain section were stained with modified Bielschowsky, Nissl staining, and modified Congo red staining. Modified Bielschowsky gives a good compromise between sensitivity for plaques and tangles can be used as a single stain for diagnosis of AD. Briefly, sections were deparaffinized through xylene and alcohols into tap water before being placed into fresh 20% silver nitrate solution for 20 min. After washing thoroughly with distilled water, slides were immersed in 20% silver nitrate solution titrated with fresh sodium hydroxide and evaporated ammonia (200 ml of 28% ammonium hydroxide by leaving in an open beaker for 20 min in a fume cupboard). After 15 min, slides were washed with ammonia water before being individually developed with 100 ml of developer (20 ml of formaldehyde, 100 ml distilled water, 20 μ l concentrated nitric acid, and 0.5 g citric acid) and then added to 50 ml of titrated silver nitrate solution. Slides were then rinsed in tap water, fixed in 5% sodium thiosulfate, and dehydrated through alcohols and xylene. Congo red staining is an accepted histochemical marker for the β -pleated-sheet structure of amyloid. Sections were

deparaffinized through xylene and alcohols into tap water. Afterwards, slides were immersed in alkaline sodium chloride. After 20 min, they were immersed in alkaline Congo red solution for 20 min and then differentiated with alcoholic potassium. After this, slides were counterstained with alum hematoxylin and dehydrated through alcohols and xylene. All of the cerebral cortex and molecular layer cells in the CA1 region were counted on Nissl stained under a light microscope at 40 \times magnification. Four contiguous 0.936 mm² areas in cortex and 0.26 mm² areas in hippocampus were counted. Measurement of the area was performed using the Olysia BioReport software imaging system (Olympus Corporation, Tokyo, Japan) [20] and neuritic plaques were counted on modified Bielschowsky stained separately in cortical regions and hippocampus at 100 \times magnification.

TUNEL procedures. Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining for apoptotic neurons was performed according to the manufacturer's instruction [21]. Cell death was detected *in situ* in resected tissues by enzymatic labeling of DNA strand breaks using a TUNEL assay according to the manufacturer's instructions. Paraffin-embedded tissue were deparaffinized in xylene and rehydrated with ethanol series (absolute, 95%, 90%, 80%, 70%, diluted in double distilled water). After this stage and all subsequent stages, washing with PBS was performed. The sections were treated with proteinase K (20 μ g/ml in 10 mM Tris/HCl, pH 7.6) for 30 minutes, the endogenous peroxidase activity was blocked by using 0.3% H₂O₂ in methanol for 30 minutes. Then, the sections were prepared with permeabilization solution (0.1% Triton X-100, 0.1% sodium citrate) for 15 minutes. The labeling of apoptosis was induced by TdT, which catalyses deoxyribonucleotide, and fluorescein conjugated dUTP. During this step, slides were coverslipped and incubated in a humidity chamber at 37°C for 60 minutes. Then, the sections were washed and incubated with a convertor-POD at 37°C in a humidity chamber for 30 minutes. After a wash, color was developed by incubating sections with a diaminobenzidine substrate solution for 15 minutes. After a final wash, sections were viewed by light microscopy and only those cells with positive TUNEL staining and of apoptotic morphology were considered apoptotic [22].




Fig. 1. Percent of alternation behavior in Y-maze task in studied groups (mean \pm SEM). * $P < 0.0001$ as compared to sham and control groups.

Statistical analysis. All results were performed as mean \pm S.E.M. for the behavioral tests including passive avoidance test and Y-maze task and Neuronal counts in cerebral cortex and CA1, one-way analysis of variance (ANOVA) was used. Normality and homogeneity of the data were confirmed before ANOVA analysis. In all analyses, a P value of < 0.05 was considered statistically significant.

RESULTS

Y-maze task. For Y-maze task, short-term spatial memory performance was examined in this study. The mean scores of alternation behavior for sham, control, and AD group were 80.56, 86.7, and 46.2%, respectively. AD group showed a significant reduction in alternation behavior as compared to control and sham group ($P < 0.0001$, Fig. 1). There




Fig 2. Single-trial passive avoidance test. Initial latency of control and sham rats compared to AD group, * $P < 0.0001$.

was no significant difference between sham and control groups.

Single-trial passive avoidance test. The performance of control and AD group rats for passive avoidance test was shown by initial and step-through latency. The AD group rats indicated significant damage in retention in passive avoidance test. The mean of acquisition in passive avoidance test showed a non-significant decrease in sham group compared to control group. This result exhibited significantly decreased acquisition to passive avoidance response in AD group compared to control and sham group ($P < 0.0001$, Fig. 2).

Histological procedure. Two types of plaque were seen in AD cerebral cortices, diffuse plaques and compacted amyloid cores. In this study by Bielschowsky silver staining, diffuse plaques were detected in the cerebral cortex and hippocampus (Fig. 3). These diffuse cerebral plaques ranged in size smaller than $210 \mu\text{m}$. In this study, the number of plaques in hippocampus was more than cortex and white matter. Also, neuronal population reduction in hippocampus was observed comparing to cortex. The perivascular amyloid deposits were seen clearly in cortex, hippocampus and white matter. Dystrophic neurites were not seen associated with diffuse plaques. Diffuse plaques were not found with reactive neurites or glial cells. Compacted amyloid cores were present in the cerebral cortex, hippocampus and white matter. scattered amyloid cores were seen by Congo red and Bielschowsky silver stain in AD cortex and hippocampus. Rare amyloid angiopathy was detected in the cerebrum, hippocampus and white matter in AD group (Fig. 3). Congo red staining showed evidence of some birefringent material indicating the presence of fibrillar structures. Congo red staining slides showed typical green birefringence under polarized light in AD group (Fig. 4). Nissl-stained neuronal densities indicated AD group (Fig. 5) had consistent reduction of neuron densities 55.6% in the CA1 and 25.9% in cortex. The number of plaques in the hippocampus were present 11 ± 2 diffuse plaques and 3 ± 1 cored plaques per $100\times$ field and the neuritic plaques in cerebral cortex showed numerous 7 ± 2 diffuse plaques and 2 ± 1 cored plaques per $100\times$ field (Table 1).

TUNEL procedure. TUNEL staining was used to show apoptosis (Fig. 6). Brain tissue sections from AD cases showed comprehensive cellular




Fig. 3. Modified Bielschowsky staining. AD group: cerebral cortex (A, B, and J), hippocampus (C, D and H), white mater (E) and blood vessels (F and G). (A) cerebral diffuse plaques in the cortex (40×); (B) compacted amyloid cores plaques in the cortex (40×); (C1) compact plaques in CA1 region in Hippocampus (40×); (C2) diffuse plaques in CA1 region in Hippocampus; (D1) compact plaques in Hippocampus parenchyma (40×); (D2) neurofibrillary tangles in CA1; (E1) compact plaques in white mater (40×); (E2) amyloid deposits in blood vessels (40×); (F1) and (F2) blood vessels Bielschowsky staining (40×); (G) amyloid angiopathy in arteriole (100×); (H1) compact plaques in white mater (40×); (H2) amyloid deposits in blood vessels; (J) cortex in control group (40×).

DNA fragmentation revealed by TUNEL. This method detected primarily double-stranded DNA breaks via TdT. In AD group in CA1 region of hippocampus and cortex, TUNEL-positive cells were observed.

DISCUSSION

In this study, we demonstrated diffuse plaques and compacted amyloid cores by modified Bielschowsky silver staining in the cerebral cortex and hippocampus. Also, we showed the increased

number of plaques and decreased neuronal population in hippocampus compared to cortex and white matter by modified Congo red staining that showed typical green birefringence under polarized light in AD group. For evaluation of behavioral changes in small animals such as rats and mice, the following methods have been used: (1) passive avoidance response, (2) active avoidance response, and (3) the maze test [9]. In this study, passive avoidance response and maze test were used to appraise the preservation of memory after A β effects. The AD groups that received A β , showed

Table 1. Neuronal counts in cerebral cortex and CA1.

Group	Region	Neurons per mm ²	Average of neurons per field	Std. deviation
AD	CA1	2.920*	76.0	1.491
	Cortex	0.294*	275.0	7.454
control	CA1	6.35 ^{0**}	165.0	3.830
	Cortex	0.397**	374.1	2.066
Sham	CA1	6.250	162.6	0.843
	Cortex	0.392	366.5	1.509

* $P < 0.0001$, AD group compared with control and sham groups; ** $P > 0.05$, control group compared with sham group.




Fig. 4. Tissue obtained with Congo red staining from AD group (40×). **(A)** amyloid deposits in CA1 region; **(B)** typical green birefringence amyloid deposits under polarized light and **(C)** control group (40×).

significant decrease in behavior scores in comparison with the control and sham group in Y-maze test and passive avoidance response. This study similar to other studies in this field confirmed that deposition of A β in AD brains impairs learning and memory [1, 8, 12]. The passive avoidance procedure is a quick and simple task to administer [23]. Therefore, this procedure is widely used to measure cognitive alterations after drug administration, lesions, and behavioral manipulations [24]. The passive avoidance test has been widely used to evaluate rodent working memory ability in association with cortical and hippocampal functions [25]. In this study, the latency periods of passive avoidance response were evaluated in these rats and the retention of memory was significantly disturbed in AD group. The neurotransmitters in the

central nervous system have important roles in normal functioning and behavior of the adult individual. They interact with each other in complex networks in the process of learning and memory, in which acetylcholine is proposed to have a central




Fig. 5. Nissl staining AD group. **(A)** CA1 Nissl staining AD group (40×): (1) cell death and (2) apoptotic body; **(B)** control group (40×).




Fig. 6. Cell death detection *in situ* by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL). Cells with positive TUNEL staining (brown) and exhibiting apoptotic morphology were considered apoptotic. **(A1)** AD group TUNEL positive in cortex; **(A2)** apoptosis; **(B)** control group TUNEL negative in cortex; **(C1)** AD group TUNEL positive in CA1; **(C2)** apoptosis; **(D)** control group TUNEL negative in CA1 (40×).

role. Acetylcholinesterase is an enzyme responsible for hydrolyzing and so deactivating acetylcholine in the body. Alterations in this enzyme level are indicative of impairment of cholinergic function [26]. Several studies have reported that infusing A β peptide (1-40) into the rat cerebral ventricle induces learning impairment, neuronal and morphological degeneration and alteration of enzyme markers such as acetylcholine esterase and choline acyltransferase; all of which are well-known characteristics of AD [27]. The hippocampus and the cerebral cortex are the key structures of memory formation; A β injection into hippocampus can deficit in both synaptic transmission and plasticity [28, 29, 30] and neuronal dysfunction [31].

In the present study, cerebral plaques of the diffuse type were present only in AD group. The cerebral lesions observed in cases of AD are definable as diffuse plaques because they appear to lack dystrophic neurites and that is dispersed rather than compacted into a core. An alternative view could be that diffuse plaques are a separate plaque type which does not evolve further in the cerebral cortex. We did not detect morphologic changes in any of the cells or processes in areas of cortex containing abundant diffuse plaques. Injection of A β protein is widely used in AD model preparation. A β proteinosis is an important structure of senile plaques and is thought to be the main reason for the loss of neurons and the resulting memory disability [32].

In present survey in the AD group, it was shown that A β to be caused DNA damage in neurons that finally degenerate and die. Apoptotic and necrotic changes that make neuronal cell death occur in AD brains. Multiple laboratories have reported evidence for apoptosis, or programmed cell death, in pathological tissues obtained from the brains of AD patients [33]. Although TUNEL is not a definitive marker of apoptosis, it still allows identification of dying cells *in situ* [32, 33]. Lassmann *et al.* [34] also reported that TUNEL-positive cells were positioned in brain regions containing extracellular A β deposition. In this regard, although there has been some debate on whether amyloid deposition correlates with the degree of dementia [35], recent evidence indicates that the severity of dementia can be correlated with the A β load [36]. This does not, however, imply that other factors such as cytoskeletal abnormalities are not also involved in the disease process [37].

REFERENCES

1. Wu, Q.Y., Li, J., Feng, Z.T. and Wang, T.H. (2007) Bone marrow stromal cells of transgenic mice can improve the cognitive ability of an Alzheimer's disease rat model. *Neurosci. Lett.* 417: 281-285.
2. Markesbery, W.R. and Carney, J.M. (1999) Oxidative alterations in Alzheimer's disease. *Brain Pathol.* 9: 133-146.
3. Behl, C., Davis, J.B., Lesley, R. and Schubert, D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. *Cell* 77: 817-827.
4. Katzman, R. and Saitoh, T. (1991) Advances in Alzheimer's disease. *FASEB J.* 5: 278-286.
5. Butterfield, D.A. and Stadtman, E.R. (1997) Protein oxidation processes in aging brain. *Adv. Cell Aging Gerontol.* 2: 161-191.
6. Selkoe, D.J. (1996) Amyloid beta-protein and the genetics of Alzheimer's disease. *J. Biol. Chem.* 271: 18295-18298.
7. Underwood, J.C.E (2009) General and systematic pathology. 5th ed, Churchill Livingstone, NY, USA. pp. 779-781.
8. Wevers, A., Witter, B., Moser, N., Burghaus, L., Banerjee, C., Steinlein, O.K., Schutz, U., de Vos, R.A., Steur, E.N., Lindstrom, J. and Schroder, H. (2000) Classical Alzheimer features and cholinergic dysfunction: towards a unifying hypothesis? *Acta Neurol. Scand. Suppl.* 176: 42-48.
9. Perry, E.K., Perry, R.H., Blessed, G. and Tomlinson, B.E. (1977) Necropsy evidence of central cholinergic deficits in senile dementia [letter]. *Lancet* 1: 189.
10. Whitehouse, P.J., Price, D.L., Clark, A.W., Coyle, J.T. and DeLong, M.R. (1981) Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. *Ann. Neurol.* 10:122-126.
11. Kumar, V., Abbas, A.K., Fausto, N., Aster, J. Robbins and Cotran (2010) Pathologic Basis of Disease. 8th ed., Saunders, New York, USA. pp. 1313-1319.
12. Lo'pez-Toledano, M.A. and Shelanski, M.L. (2004) Neurogenic Effect of β -Amyloid Peptide in the Development of Neural Stem Cells. *J. Neuroscience* 24 (23): 5439-5444.
13. Selkoe, D.J. (1997) The molecular pathology of Alzheimer's disease. *Neuron* 16: 487-498.
14. Hyman, B.T., Van Hoesen, G.W., Damasio, A.R. and Barnes, C.L. (1984) Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. *Science* 225: 1168-1170.
15. Wallenstein, G.V.H. and Hasselmo, M.E. (1998) The hippocampus as an associator of discontinuous events. *Trends Neurosci.* 21: 317-323.
16. Bures, J., Buresová, O. and Huston, J.P. (1983) Techniques and basic experiments for the study of brain and behavior. *Elsevier Academic Publishers, Netherlands.*
17. Bursztajn, S.H., DeSouza, R., McPhie, D.L., Berman,

- S.A., Shioi, J., Robakis, N.K. and Neve, R.L. (1998) Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis. *J. Neuroscience*. 18: 9790-9799.
18. Verbeek MM, Vinters H, and de Waal RM. (2000). Cerebrovascular Amyloidosis in Alzheimer's Disease and Related Disorders. *Amsterdam: Kluwer, In press*.
 19. Roghani, M., Joghataie, M.T., Jalali, M.R. and Baluchnejadmojarad, T. (2006) Time course of changes in passive avoidance and Y-maze performance in male diabetic rats. *Iran. Biomed. J.* 10: 99-104.
 20. Kowall, N.W., Beal, M.F., Busciglio, J., Duffy, L.K., Yankner, B.A. (1991) An *in vivo* model for the neurodegenerative effects of beta amyloid and protection by substance. *Proc. Natl. Acad. Sci.* 88: 7247-7251.
 21. Gavrieli, Y., Sherman, Y. and Ben-Sasson, S.A. (1992) Identification of programmed cell death *in situ* via specific labeling of nuclear DNA fragmentation. *J. Cell Biol.* 119: 493-501.
 22. Bennett, M.W., O'Connell J., O'Sullivan, G.C., Roche, D., Brady, C., Kelly, J., Collins, J.K. and Shanahan, F. (1999) Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. *Gut.* 44:156-162.
 23. Sahgal A. (1993) Passive avoidance procedure. In: Sahgal A, ed. *Behavioral Neuroscience: Volume 1: A Practical Approach. Oxford, England: IRL Press; 49-56*.
 24. Shimizu-Sasamata, M., Yamamoto, M., Okada, M., Yamaguchi, T. and Tamura, A. (1992) Effects of indeloxazine hydrochloride on behavioral and biochemical changes in chronic phase of focal cerebral ischemia in rats. *Arch. Int. Pharmacodyn. Ther.* 314: 74-89.
 25. Jacqueline, N.C. (2000) Learning and Memory What's wrong with my mouse? WLLET-LISS, Canada. p. 99.
 26. Kaoud, H.A., Kamel, M.M., Abdel-Razek, A.H., Kamel, G.M. and Ahmed, K.A. (2010) Neuro-behavioural, neurochemical and neuromorphological effects of cadmium in male rats. *J. Am. Sci.* 6: 189-202.
 27. Hashimoto, M., Hossain, S., Shimada, T., Sugioka, K., Yamasaki, H., Fujii, Y., Ishibashi, Y., Oka, J. and Shido, O. (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. *J. Neurochem.* 81: 1084-1091.
 28. Shirai, N. and Suzuki, H. (2004) Effect of dietary docosahexaenoic acid and catechins on maze behavior in mice. *Ann. Nutr. Metab.* 48: 51-58.
 29. Nobakht, M., Najafzadeh N. and Kordestani Shargh B. (2009) Effects of tamoxifen on morphological and ultrastructural aspects of developing hippocampus of rat. *Iran. Biomed. J.* 13: 237-243.
 30. Stephan, A., Laroche, S. and Davis, S. (2001) Generation of aggregated β -amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. *J. Neurosci.* 21: 5703-5714.
 31. Koudinov, A.R., Berezov, T.T. and Koudinova, N.V. (2001) Amyloid plaque (and not diffuse amyloid) is a condition for neuronal dysfunction. *Clin. Med. Health Res.* :9-16.
 32. Li, Y., Chopp, M., Chen, J., Wang, L., Gautam, S.C., Xu, Y.X. and Zhang, Z. (2000) Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. *J. Cereb. Blood Flow Metab.* 20: 1311-1319.
 33. Guo, Q, Fu, W., Xie, J., Luo, H., Sells, S.F., Geddes, J.W., Bondada, V., Rangnekar, V.M. and Mattson, M.P. (1998) Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. *Nat. Med.* 4: 957-962.
 34. Lassmann, H., Bancher, C., Breitschopf, H., Wegiel, J., Bobinski, M., Jellinger, K. and Wisniewski H.M. (1995) Cell death in Alzheimer's disease evaluated by DNA fragmentation *in situ*. *Acta Neuropathol.* 89: 35-41.
 35. Hyman, B.T., Marzloff, K. and Arriagada P.V. (1993) The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. *J. Neuropathol. Exp. Neurol.* 52: 594-600.
 36. Cummings, B.J. and Cotman C.W. (1995) Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. *Lancet* 346: 1524-1528.
 37. Terry, R.D. (1996). The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. *J. Neuropathol. Exp. Neurol.* 55: 1023-1025.